Chitosan as an adjuvant for poliovaccine

Journal of Medical Virology

Volumn 83, Issue 5, 2011, Pages 847-852

  Ghendon, Y ^a   Markushin, S ^a   Akopova, I ^a   Koptiaeva, I ^a   Krivtsov, G ^a  

^a MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

Author keywords

Adjuvant; Chitosan; Poliovaccine; Poliovirus

Indexed keywords

CHITOSAN DERIVATIVE; CHITOSAN GLUTAMATE; CHITOSAN SULFATE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; RAT; VACCINATION; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHITOSAN; FEMALE; MICE; MICE, INBRED BALB C; POLIOVIRUS VACCINES; RATS; RATS, WISTAR; VACCINES, INACTIVATED;

HUMAN POLIOVIRUS 1; MUS; POLIOVIRUS; RATTUS;

EID: 79952727885     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22030     Document Type: Article

References (19)

1. Aguilar JC, Rodriguez EG. 2007. Vaccine adjuvants revisited. Vaccine 25: 3752-3762.
2. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. 2006. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43: 1135-1142.
3. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. 2009. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4: e4384.
4. Ghendon Y, Markushin S, Krivtsov G, Akopova I. 2008. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol 153: 831-837.
5. Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, Borisova O, Ahmatova N, Kurbatova E, Mazurina S, Gervazieva V. 2009. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol 81: 494-506.
6. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines-Current status, problems and future prospects. Vaccine 13: 1263-1276.
7. Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15: 1326-1331.
8. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51: 81-96.
9. Ivanov AP, Dragunsky EM, Chumakov KM. 2006. 1, 25-Dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 193: 598-600.
10. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. 2008. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3: c1665.
11. Markushin SG, Ahmatova NK, Krivtsov GG, Pereverzev AD, Akopova II, Koptiaeva IB, Borisova OV. (in press). Features of immune response after immunization of mice with inactivated poliovaccine adjuvanted with chitosan preparations. Russian Immunol J.
12. Singla AK, Chawla M. 2001. Chitosan: Some pharmaceutical and biological aspects-An update. J Pharm Pharmacol 53: 1047-1067.
13. World Health Organization. 2002. Recommendations for the Production and Control of Poliomyelitis Vaccine (Inactivated). In: WHO Expert Committee on Biological Standardization. Fifty-first report. Geneva, Switzerland: World Health Organization. WHO Technical Report Series, 910, Annex 2.
14. World Health Organization. 2004. Polio Laboratory Manual 4th edition. Document WHO/IVB/04.10. Geneva, Switzerland: World Health Organization.
15. World Health Organization. 2009a. Progress towards interrupting wild poliovirus transmission worldwide, 2008. Wkly Epidemiol Rec 84: 110-116.
16. World Health Organization. 2009b. Global detection of wild and vaccine derived polioviruses, January 2008-June 2009. Wkly Epidemiol Rec 84: 366-370.
17. World Health Organization. 2010. Conclusions and recommendations of the advisory committee on poliomyelitis eradication, November 2009. Wkly Epidemiol Rec 85: 1-11.
18. World Health Assembly. 1988. Polio eradication by the year 2000. WHO Resolution WHA 41.28, WHA41/1988/RREC/1, p. 72 Geneva, Switzerland: World Health Organization.
19. Yang C, Shi H, Zhou J, Liang Y, Xu H. 2008. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 27: 6558-6563.